The EndBrainCancer Initiative Announces Partnership with GT Medical Technologies, Creators of GammaTile Therapy for Patients with Brain Tumors
30 Jun, 2020, 06:26 ET
SEATTLE, June 30, 2020 /PRNewswire/ -- The EndBrainCancer Initiative (EBCI) announced today that GT Medical Technologies, manufacturers of GammaTile Therapy for Brain Cancer Patients, has joined EBCI's roster of corporate partners. According to the EndBrainCancer Initiative, GT Medical Technologies is dedicated to improving the lives of patients with brain tumors through a promising new intervention in the treatment of brain cancer, GammaTile® Therapy. Part of EBCI's business model is to partner with other companies that are also offering promising new treatment options to treat brain cancer including metastatic disease to the brain.
GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for patients with newly diagnosed malignant and recurrent brain tumors including primary and metastatic tumors. The small, bioresorbable GammaTile:
- Is placed directly and surgically at the tumor site after the tumor is surgically removed.
- Provides immediate radiation treatment to remaining tumor cells before they can replicate while preserving healthy tissue.
- Means no additional trips to the hospital or clinic for standard radiation therapy
- Allows patients to receive radiation treatment while going about their daily lives.
According to the EndBrainCancer Initiative, the partnership with will result in:
- Education, Awareness & Outreach about GammaTile Therapy to a National audience of patients with brain tumors, their caregivers, medical practitioners, industry, and the general public with a total annual reach of over 18,000,000.
- Patients facing surgery and radiation who contact EBCI's "Direct Connect" Patient Services Program and Referral Clinic being provided with information about GammaTile Therapy
- IMMEDIATE ACCESS to brain tumor specialists and cancer centers across the country where GammaTile Therapy is offered for those patients who express interest (to get connected please fill out a Patient Advocacy & Inquiry Form or call 425.445.2215).
"We are proud to welcome GT Medical Technologies as an EBCI Corporate Partner," commented Dellann Elliott Mydland, EBCI President & CEO. "Representing a breakthrough in delivering radiation, GammaTile Therapy is a triple win for patients with brain cancer that it:
- Has been shown to delay brain tumor recurrence, potentially extending survival
- Minimizes side effects and eliminates all those trips to the hospital or clinic that standard radiation requires.
- Allows patients and their caregivers to focus on healing, doing those things that are important to them as well as time to explore all of their treatment options, which also include Standard of Care (SOC), advanced treatments, clinical trials and the Optune device."
"We look forward to bringing on additional Corporate Partners who share EBCI's commitment to improving the lives and extending survivorship for this patient population and who are 'moving the dial' through making available new options for treating this disease." To become a Corporate Partner, please contact Dellann Elliott Mydland directly at [email protected], 425-785-8489 or fill out our Partnership Inquiry Form.
About the EndBrainCancer Initiative
The EndBrainCancer Initiative (EBCI, formerly the Chris Elliott Fund) is a national brain cancer and brain tumor patient advocacy and services organization and 501(c) 3 social enterprise with offices and its "Direct Connect" Center & Referral Clinic located in Redmond, Washington. Established in 2002 and now celebrating 18+ years of service, EBCI is committed to finding a cure for brain cancer and bringing HOPE to the lives of patients and their families through its programs:
- "Direct Connect" Patient Services Program and Referral Clinic
- Brain Tumor Disease Education, Awareness, and Outreach Program
- Brain Tumor Patient Advocacy and Access
- First Step Initiative and our Team Up Initiative
Since its founding, EBCI has helped thousands of patients, caregivers, and their families and has become a credible and trusted resource at all levels in the brain cancer treatment community from patients to research institutions to pharmaceutical and regulatory entities advocating on the National and State level for the approval and reimbursement of new therapies for cancer patients.
Please contact us at [email protected] or 425.444.2215. To support EBCI's efforts, programs, and free services, provide a gift, designate funds, sponsorship or grant today contact us at www.endbraincancer.org
Media Contact: Dellann Elliott Mydland
425.785.8489 | [email protected]
SOURCE End Brain Cancer Initiative (EBCI)
Share this article